The epidemiology of respiratory viruses shifted considerably following the COVID-19 pandemic and the subsequent rollback of non-pharmaceutical interventions (NPIs). The initial global containment strategies implemented during the SARS-CoV-2 outbreak profoundly altered viral transmission dynamics and circulation patterns. As the World Health Organization (WHO) declared COVID-19 no longer a public health emergency in May 2023, viral circulation began reverting to pre-pandemic trends. This retrospective observational study examined the evolving epidemiological patterns of respiratory infections during and after the lifting of NPI, assessing associated clinical manifestations and their relationship with patient-specific risk factors. Data were collected from 307 patients tested between October 2021 and December 2024 using a respiratory multiplex PCR at the Rodolphe Mérieux Laboratory in Lebanon. Results revealed a reemergence of pre-pandemic seasonal trends for most viruses. Rhinovirus remained the most prevalent pathogen, likely due to the absence of a vaccine. Respiratory syncytial virus (RSV) and Influenza A resumed their characteristic winter peaks, while human metapneumovirus (HMPV) showed no co-infections, suggesting viral interference. The persistence of Influenza A and SARS-CoV-2 appeared influenced by vaccine coverage, viral mutations, and environmental factors. Multiplex PCR testing proved to be a valuable yet costly tool for both diagnosis and epidemiological surveillance. Overall, this study highlights the importance of continued viral monitoring in the post-NPI period, reflecting both the effectiveness of NPIs in limiting viral spread and the importance of ensuring wider access to advanced diagnostic methods.
Drug-resistant tuberculosis (TB) complicates global efforts toward TB elimination. However, the introduction of new and repurposed drugs- particularly the all-oral BPaL regimen (bedaquiline, pretomanid, and linezolid)-has raised hopes due to its favorable treatment outcomes for multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB. Susceptibility to these new drugs may vary depending on the lineage of the Mycobacterium tuberculosis (MTB) strain. Within the framework of a research project investigating the association between potential resistance-associated nucleotide variants and MTB lineages, we used the proprietary pipeline TB-Annotator to analyze 125,000 publicly available Short Read Archive datasets from NCBI. We identified 65 mutations across 65 clonal complexes of the lineage 2 (L2), that share at least one SNP within a list of 14 genes potentially involved in drug resistance to BPaL. During this large-scale genomic screening, we identified a previously uncharacterized clonal complex of 49 SRAs that did not belong to any previously described ancient or modern L2-sublineages (modern 1 to modern 6). We therefore performed a comparative genomic analysis on a representative set of L2 isolates to fully characterize this group. These 49 SRAs are found in an independent branch of the L2 phylogenetic tree. They share 4 SNPs, including an Ile-to-Leu substitution in the product of fbiD, and are organized into two subclusters, with an intra-sublineage SNP distance of around 150 ± 50 SNPs. We named this novel sublineage L2.2-M7. Further functional validation-through phenotypic drug susceptibility testing and gene replacement-is needed to determine whether this fbiD mutation confers resistance to pretomanid. Global genomic surveillance of this emerging sublineage is warranted to monitor its spread and clinical relevance in the era of new TB treatment regimens.
1 October 2026 in International Journal of Infectious Diseases